The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

43 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Quinazoline derivatives as selective CYP1B1 inhibitors.EBI
Birla Institute of Technology
Synthesis, evaluation and molecular modelling studies of 2-(carbazol-3-yl)-2-oxoacetamide analogues as a new class of potential pancreatic lipase inhibitors.EBI
Birla Institute of Technology
Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.EBI
Birla Institute of Technology
Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities.EBI
Birla Institute of Technology
Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors.EBI
Birla Institute of Technology
Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.EBI
Birla Institute of Technology
Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.EBI
Birla Institute of Technology
Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors.EBI
Birla Institute of Technology
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.EBI
Birla Institute of Technology
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.EBI
Birla Institute of Technology
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors.EBI
Birla Institute of Technology
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain.EBI
Birla Institute of Technology
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.EBI
Birla Institute of Technology
Development of novel tetrahydrothieno[2,3-c]pyridine-3-carboxamide based Mycobacterium tuberculosis pantothenate synthetase inhibitors: molecular hybridization from known antimycobacterial leads.EBI
Birla Institute of Technology
Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.EBI
Birla Institute of Technology
Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.EBI
Birla Institute of Technology
Discovery of novel inhibitors targeting the Mycobacterium tuberculosis O-acetylserine sulfhydrylase (CysK1) using virtual high-throughput screening.EBI
Birla Institute of Technology
Additional acetyl cholinesterase inhibitory property of diaryl pyrazoline derivatives.EBI
Birla Institute of Technology
Novel acridinedione derivatives: design, synthesis, SIRT1 enzyme and tumor cell growth inhibition studies.EBI
Birla Institute of Technology
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.EBI
Birla Institute of Technology
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.EBI
Birla Institute of Technology
Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.EBI
Birla Institute of Technology
Development of selective and reversible pyrazoline based MAO-B inhibitors: virtual screening, synthesis and biological evaluation.EBI
Birla Institute of Technology
Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.EBI
Birla Institute of Technology
A short survey of dengue protease inhibitor development in the past 6 years (2015-2020) with an emphasis on similarities between DENV and SARS-CoV-2 proteases.EBI
Birla Institute of Technology
Phytoestrogens and their synthetic analogues as substrate mimic inhibitors of CYP1B1.EBI
Birla Institute of Technology
Design and synthesis of potent and multifunctional aldose reductase inhibitors based on quinoxalinones.EBI
Birla Institute of Technology
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, IX and XII with benzene sulfonamides incorporating 4- and 3-nitrophthalimide moieties.EBI
Birla Institute of Technology
Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.EBI
Birla Institute of Technology
Carbonic anhydrase inhibitors: synthesis and inhibition of the human carbonic anhydrase isoforms I, II, VII, IX and XII with benzene sulfonamides incorporating 4,5,6,7-tetrabromophthalimide moiety.EBI
Birla Institute of Technology
Carbonic anhydrase inhibitors: Synthesis and inhibition of the cytosolic mammalian carbonic anhydrase isoforms I, II and VII with benzene sulfonamides incorporating 4,5,6,7-tetrachlorophthalimide moiety.EBI
Birla Institute of Technology
Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.EBI
Birla Institute of Technology
Design, synthesis, biological evaluation and molecular modelling studies of novel diaryl substituted pyrazolyl thiazolidinediones as potent pancreatic lipase inhibitors.EBI
Birla Institute of Technology
Cyclic P1 linkers as factor XIa inhibitorsBDB
Bristol-Myers Squibb
Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related theretoBDB
Arena Pharmaceuticals
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.BDB
Massachusetts General Hospital and Harvard Medical School
(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).BDB
Johnson & Johnson Pharmaceutical Research and Development
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.BDB
Croissy-Sur-Seine Paris
Inhibitors designed for the active site of dihydroorotase.BDB
Texas A&M University
Mediation by 5-hydroxytryptamine2B receptors of endothelium-dependent relaxation in rat jugular vein.BDB
Smithkline Beecham Pharmaceuticals
Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.BDB
University of Auckland